DOP36: Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter studyECCO'22Year: 2022
Authors: Sallette, M.(1);Bouhnik, Y.(2);Nachury, M.(3);Bellanger, C.(4);Laharie, D.(5);Amiot, A.(6);Peyrin-Biroulet, L.(7);Roblin, X.(8);Altwegg, R.(9);Buisson, A.(10);Reenaers, C.(11);Bouguen, G.(12);Vuitton, L.(13);Bourreille, A.(14);Gilletta, C.(15);Serrero, M.(16);Hébuterne, X.(17);Filippi, J.(18); Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
(1)Archet 2 University Hospital, Gastroenterology, Nice, France;(2)Beaujon University Hospital, Gastroenterology, Paris, France;(3)Lille University Hospital, Gastroenterology, Lille, France;(4)Kremlin Bicêtre Hospital, Gastroenterology, Paris, France;(5)Haut Lévêque Hospital, Gastroenterology, Bordeaux, France;(6)Henri Mondor University Hospital, Gastroenterology, Paris, France;(7)Nancy University Hospital, Gastroenterology, Nancy, France;(8)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(9)Montpellier University Hospital, Gastroenterology, Montpellier, France;(10)Clermont-Ferrand University Hospital, Gastroenteroogy, Clermont-Ferrand, France;(11)Liège University Hospital, Gastroenterology, Liège, Belgium;(12)Rennes University Hospital, Gastroenterology, Rennes, France;(13)Besançon University Hospital, Gastroenterology, Besançon, France;(14)Nantes University Hospital, Gastroenteroogy, Nantes, France;(15)Toulouse University Hospital, Gastroenterology, Toulouse, France;(16)Nord University Hospital, Gastroenterology, Marseille, France;(17)Archet 2 University Hospital, Gastroenterology, Nice, France;(18)Archet 2 Unversity Hospital, Gastroenterology, Nice, France;
DOP37: Efficacy and safety of filgotinib in patients with Ulcerative Colitis stratified by age: Post hoc analysis of the phase 2b/3 SELECTION and SELECTIONLTE studiesECCO'22Year: 2022
Authors: SCHREIBER, S.(1);Loftus Jr, E.V.(2);Maaser, C.(3);Danese, S.(4,5);Rudolph, C.(6);Jongen, R.(6);De Haas, A.(6);Oortwijn, A.(6);Vermeire, S.(7);
(1)Kiel University, Medicine I, Kiel, Germany;(2)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(3)Hospital Lüneburg, Outpatients Department of Gastroenterology, Lüneburg, Germany;(4)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(5)Vita-Salute, San Raffaele University, Milan, Italy;(6)Galapagos, Nv, Leiden, The Netherlands;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
DOP38: Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1ECCO'22Year: 2022
Authors: Vermeire, S.(1);Colombel, J.F.(2);Takeuchi, K.(3);Gao, X.(4);Panaccione, R.(5);Danese, S.(6);Dubinsky, M.(7);Schreiber, S.(8);Ilo, D.(9);Finney-Hayward, T.(9);Zhou, W.(9);Phillips, C.(9);Yao, X.(9);Zhou, Q.(9);Loftus, E.(10);
(1)University Hospital Leuven, none, Leuven, Belgium;(2)Icahn School of Medicine at Mount Sinai, none, New York City, United States;(3)Tsujinaka Hospital Kashiwanoha- Kashiwa, Division of Gastroenterology and Hepatology, Chiba, Japan;(4)The Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(5)University of Calgary, Division of Gastroenterology and Hepatology, Alberta, Canada;(6)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Department of Gastroenterology and Endoscopy, Milan, Italy;(7)Icahn School of Medicine at Mt Sinai, Department of Pediatric Gastroenterology, New York, United States;(8)University Hospital Schleswig-Holstein, none, Kiel, Germany;(9)AbbVie- Inc, none, North Chicago, United States;(10)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP39: Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programmeECCO'22Year: 2022
Authors: Higgins, P.(1);Colombel, J.F.(2);Reguiero, M.(3);Parkes, G.(4);Ilo, D.(5);Philips, C.(5);Yao, X.(6);Cheng, E.(6);Schreiber, S.(7);
(1)University of Michigan, Department of Internal Medicine, Ann Arbor, United States;(2)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(3)Cleveland Clinic Foundation, Department of Gastroenterology and Hepatology, Cleveland, United States;(4)Royal London Hospital, Department of Gastroenterology, London, United Kingdom;(5)AbbVie Inc, Research and Development, North Chicago- Illinois, United States;(6)AbbVie Inc, Data & Statistical Sciences, North Chicago- Illinois, United States;(7)University Hospital Schleswig-Holstein, Department of Internal Medicine, Kiel, Germany;
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative ColitisECCO'22Year: 2022
Authors: Raine, T.(1);Ishiguro, Y.(2);Rubin, D.(3);Finney-Hayward, T.(4);Dapo, I.(5);Phillips, C.(5);Cheng, E.(6);Targownik, L.(7);Loftus- Jr., E.V.(8);
(1)Addenbrooke's Hospital- Cambridge University Hospitals, Department of Gastroenterology, Cambridge, United Kingdom;(2)Hirosaki General Medical Centre- National Hospital Organisation, Department of Clinical Research, Hirosaki, Japan;(3)The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(4)AbbVie Ltd., Gastroenterology, Maidenhead, United Kingdom;(5)AbbVie Ltd., Research and Development, North Chicago, United States;(6)AbbVie Ltd., Data & Statistical Science, North Chicago, United States;(7)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology and Hepatology, Toronto, Canada;(8)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;
DOP41: Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative ColitisECCO'22Year: 2022
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Klaff, J.(3);Ilo, D.(3);Yao, X.(4);Levy, G.(5);Higgins, P.D.R.(6);Loftus- Jr., E.V.(7);Panaccione, R.(8);
(1)University Hospital Leuven & KU Leuven, Gastroenterology & Hepatology, Leuven, Belgium;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)AbbVie Inc., Research and Development, North Chicago- Illinois, United States;(4)AbbVie Inc., Data & Statistical Sciences, North Chicago- Illinois, United States;(5)AbbVie Inc., Pharmacovigilance & Patient Safety, North Chicago- Illinois, United States;(6)University of Michigan, Department of Medicine- Division of Gastroenterology, Ann Arbor- Michigan, United States;(7)Mayo Clinic- College of Medicine, Division of Gastroenterology and Hepatology, Rochester- Minnesota, United States;(8)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary- Alberta, Canada;
DOP42: Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC studyECCO'22Year: 2022
Authors: Danese, S.(1);Panaccione, R.(2);D'Haens, G.(3);Peyrin-Biroulet, L.(4);Schreiber, S.(5);Kobayashi, T.(6);Gawdis-Wojnarska, B.(7);Korga, P.(8);Aguilar, H.(9);Sharkey, B.(10);Sreih, A.(11);Radosti, C.(10);Patel, A.(10);Canavan, J.(10);Rubin, D.(12);
(1)Humanitas Research Hospital, Inflammatory Bowel Diseases Center, Milan, Italy;(2)University of Calgary, Inflammatory Bowel Disease Clinic, Calgary- Alberta, Canada;(3)Amsterdam University Medical Centers, Inflammatory Bowel Disease Unit, Amsterdam, Netherlands Antilles;(4)Nancy University Hospital, Gastroenterology, Nancy, France;(5)University Hospital Schleswig-Holstein, Gastroenterology, Kiel, Germany;(6)Kitasato University Kitasato Institute Hospital, Gastroenterology, Tokyo, Japan;(7)Twoja Przychodnia-Szczecińskie Centrum Medyczne, Gastroenterology, Szczecin, Poland;(8)Centrum Medyczne KERmed, Gastroenterology, Bydgoszcz, Poland;(9)Louisiana Research Center, Gastroenterology, Shreveport, United States;(10)Bristol Myers Squibb, Division of Immunology and Fibrosis Development, Princeton, United States;(11)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(12)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
DOP43: Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True NorthECCO'22Year: 2022
Authors: Siegmund, B.(1);Axelrad, J.(2);Pondel, M.(3);Osterman, M.T.(3);Ahmad, H.A.(3);Memaj, A.(3);Regueiro, M.(4);Armuzzi, A.(5);Afzali, A.(6);
(1)Charité – Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany;(2)NYU Langone Health, Gastroenterology, New York, United States;(3)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(4)Cleveland Clinic, Gastroenterology, Cleveland, United States;(5)Fondazione Policlinico A. Gemelli IRCCS, Catholic University of Rome, Rome, Italy;(6)The Ohio State University, Wexner Medical Center, Columbus, United States;
DOP44: Long-term use of ozanimod in patients with moderately to severely active Ulcerative ColitisECCO'22Year: 2022
Authors: Danese, S.(1);Colombel, J.F.(2);Ponich, T.(3);Jovanovic, I.(4);Bossuyt, P.(5);Longman, R.(6);Alekseeva, O.(7);Petersen, A.(8);Chitkara, D.(8);Marta, C.(8);Charles, L.(8);Rubin, D.T.(9);Afzali, A.(10);Loftus, E.V.(11);Wolf, D.C.(12);
(1)IRCCS San Raffaele Hospital, Gastroenterology, Milan, Italy;(2)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(3)Western University, Gastroenterology, London, Canada;(4)University Hospital Medical Centre Bezanijska Kosa, Gastroenterology, Belgrade, Serbia;(5)Imelda GI Clinical Research Center- Imelda General Hospital, Gastroenterology, Bonheiden, Belgium;(6)Jill Roberts Center for Inflammatory Bowel Disease- Weill Cornell Medicine, Gastroenterology, New York, United States;(7)Nizhny Novgorod Regional Clinical Hospital, Gastroenterology, Nizhny Novgorod, Russian Federation;(8)Bristol Myers Squibb, Department of Fibrosis and Immunology, Princeton, United States;(9)University of Chicago Medicine Inflammatory Bowel Disease Center, Inflammatory Bowel Disease Center, Chicago, United States;(10)The Ohio State University Wexner Medical Center, Gastroenterology, Columbus, United States;(11)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester, United States;(12)Atlanta Gastroenterology Associates, Center for Crohn’s Disease & Ulcerative Colitis, Atlanta, United States;
DOP45: Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosisECCO'22Year: 2022
Authors: Armuzzi, A.(1);Cross, R.K.(2);Lichtenstein, G.(3);Calkwood, J.(4);Pai, A.(5);Pondel, M.(5);Ahmad, H.A.(5);Charles, L.(5);Elegbe, A.(5);Petersen, A.(5);Sheffield, J.K.(5);Javed, A.(6);Hou, J.(7);Regueiro, M.(8);Wolf, D.C.(9);Long, M.(10);
(1)Fondazione Policlinico A. Gemelli IRCCS- Catholic University of Rome, Gastroenterology, Rome, Italy;(2)University of Maryland School of Medicine, Gastroenterology, Baltimore, United States;(3)University of Pennsylvania, Gastroenterology, Philadelphia, United States;(4)Minneapolis Clinic of Neurology, Neurology, Minneapolis, United States;(5)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(6)University of Chicago, Neurology, Chicago, United States;(7)Baylor College of Medicine, Gastroenterology, Houston, United States;(8)Cleveland Clinic, Gastroenterology, Cleveland, United States;(9)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, United States;(10)UNC Chapel Hill, Gastroenterology, Chapel Hill, United States;
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cellsECCO'22Year: 2022
Authors: Wottawa, F.(1);Becker, B.(2);Bakr, M.(1);Kugler, J.(1);Mayr, L.(3);Paludan, S.(4);Blumberg, R.(5);Kaser, A.(6);Adolph, T.(3);Schreiber, S.(7);Meiser, J.(2);Rosenstiel, P.(1);Aden, K.(7);
(1)University Medical Center Schleswig-Holstein Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(2)Luxembourg Institute of Health, Department of Oncology, Luxembourg, Luxembourg;(3)Medical University of Innsbruck, Department of Internal Medicine I- Gastroenterology- Hepatology- Metabolism & Endocrinology, Innsbruck, Austria;(4)Aarhus University, Department of Biomedicine, Aarhus, Denmark;(5)Brigham and Women’s Hospital- Harvard Medical School, Gastroenterology Division- Department of Medicine, Boston, United States;(6)Addenbrooke’s Hospital- University of Cambridge, Department of Medicine, Cambridge, United Kingdom;(7)University Medical Center Schleswig-Holstein Kiel, Department of Medicine I, Kiel, Germany;
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s DiseaseECCO'22Year: 2022
Authors: Pesesky, M.(1);Carty, C.L.(1);Singh, N.(2);Le Bourhis, L.(3);Rosati, E.(4);Bokemeyer, B.(5);Schreiber, S.(4);Görg, S.(6);Gittelman, R.M.(1);Dines, J.N.(2);Kaplan, I.M.(7);Zahid, H.J.(8);Baldo, L.(2);Snyder, T.M.(1);Robins, H.S.(1);Franke, A.(4);Allez, M.(3);
(1)Adaptive Biotechnologies, Innovation, Seattle, United States;(2)Adaptive Biotechnologies, Medical Affairs and Clinical Development, Seattle, United States;(3)Hôpital Saint-Louis, Hepato-Gastero-Enterologie, Paris, France;(4)Christian-Albrecht University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany;(5)Interdisciplinary Crohn Colitis Centre Minden, Crohn Colitis, Minden, Germany;(6)University Hospital of Schleswig-Holstein, Institute for Transfusion Medicine, Kiel, Germany;(7)Adaptive Biotechnologies, Partnerships, Seattle, United States;(8)Microsoft Research, Immunomics, Redmond, United States;
DOP48: Hedgehog signalling controls Th17 differentiation to drive intestinal inflammation and is a druggable target for the treatment of IBDECCO'22Year: 2022
Authors: Hanna, J.(1);Beke, F.(2);O'Brien, L.(2);Kapeni, C.(2);Chen, H.C.(2);Carbonaro, V.(2);Kim, A.(3);Kishore, K.(2);Adolph, T.E.(4);Skjoedt, M.O.(5);Skjoedt, K.(6);de la Roche, M.(7);de la Roche, M.(2);
(1)University of Cambridge, Cancer Research UK - Cambridge Institute / School of Clinical Medicine, Cambridge, United Kingdom;(2)University of Cambridge, Cancer Research UK - Cambridge Institute, Cambridge, United Kingdom;(3)Washington University in St. Louis, Washington University School of Medicine, St. Louis, United States;(4)Medical University Innsbruck, Department of Internal Medicine I- Gastroenterology- Hepatology & Endocrinology, Innsbruck, Austria;(5)University of Copenhagen, Institute of Immunology and Microbiology, Copenhagen, Denmark;(6)University of Southern Denmark, Department of Cancer and Inflammation Research, Odense, Denmark;(7)University of Cambridge, Department of Biochemistry, Cambridge, United Kingdom;
DOP49: Context-dependent roles of High-mobility group box 1 (HMGB1) during intestinal inflammation and carcinogenesisECCO'22Year: 2022
Authors: Zierz, E.(1);Foelsch, K.(1);Pelczar, P.(1);Qi, M.(2);Alawi, M.(2);Clauditz, T.(3);Gagliani, N.(4);Huber, S.(1);Huebener, P.(1);
(1)University Medical Center Hamburg-Eppendorf, I. Department of Medicine, Hamburg, Germany;(2)University Medical Center Hamburg-Eppendorf, Bioinformatics Core Facility, Hamburg, Germany;(3)University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany;(4)University Medical Center Hamburg-Eppendorf, Department of General- Visceral and Thoracic Surgery, Hamburg, Germany;Huebener
DOP50: Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primatesECCO'22Year: 2022
Authors: Wong, J.(1);Lee, D.(2);Mangada, M.(3);Yadav, V.(3);Troast, D.(4);Zhong, C.(4);Hahn, K.(4);Wang, W.(5);Ge, X.(5);Sun, L.(5);Jiang, S.(5);Wang, B.(5);Zhang, J.(5);Yan, L.(5);Nguyen, H.(6);Cui, D.(2);Bursavich, M.G.(4);Lippa, B.(4);Rogers, B.N.(7);Ray, A.S.(8);
(1)Morphic Therapeutic, Biology, Waltham -Massachusetts, United States;(2)Morphic Therapeutic, Drug Metabolism PharmacoKinetics, Waltham -Massachusetts, United States;(3)Morphic Therapeutic, Translational Sciences, Waltham -Massachusetts, United States;(4)Morphic Therapeutic, Chemistry, Waltham -Massachusetts, United States;(5)ChemPartner, Biology, Shanghai, China;(6)Morphic Therapeutic, Chemistry Manufacturing and Controls, Waltham -Massachusetts, United States;(7)Morphic Therapeutic, Biology- Translational Sciences- and Chemistry, Waltham -Massachusetts, United States;(8)Morphic Therapeutic, Biology and Translational Sciences, Waltham -Massachusetts, United States;
DOP51: Loss of PTPN23 in the intestinal epithelium results in epithelial hyperproliferation and lethal diarrhea in a microbiota dependent mannerECCO'22Year: 2022
Authors: Spalinger, M.(1);Sanchez Alvarez, R.(1);Gottier, C.(1);Montalban-Arques, A.(1);Schwarzfischer, M.(1);Niechcial, A.(1);Scharl, M.(1);
(1)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;
DOP52: Development of a host-microbe interaction workflow to reveal the cell- and condition-specific effects of a commensal bacteria upon IBDECCO'22Year: 2022
Authors: Potari-gul, L.(1);Modos, D.(1,2);Fonseca, S.(2);Madgwick, M.(1,2);Thomas, J.P.(1,3);Sudhakar, P.(1,2,4);Booth, C.(5);Stentz, R.(2);Carding, S.R.(2,6);Korcsmaros, T.(1,2);
(1)Earlham Institute- Norwich Research Park, Organisms and Ecosystems, Norwich, United Kingdom;(2)Quadram Institute Bioscience- Norwich Research Park, Gut Microbes and Health Programme, Norwich, United Kingdom;(3)Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom;(4)Translational Research Center for Gastrointestinal Disorders TARGID, KU Leuven Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium;(5)Quadram Institute Bioscience- Norwich Research Park, Core Science Resources, Norwich, United Kingdom;(6)University of East Anglia, Norwich Medical School, Norwich, United Kingdom;
DOP53: In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencingECCO'22Year: 2022
Authors: Bourgonje, A.R.(1);Andreu-Sánchez, S.(2,3);Vogl, T.(4,5);Hu, S.(1,2);Vich Vila, A.(1,2);Leviatan, S.(4,5);Kurilshikov, A.(2);Klompus, S.(4,5);Kalka, I.N.(4,5);van Dullemen, H.M.(1);Weinberger, A.(4,5);Visschedijk, M.C.(1);Festen, E.A.M.(1);Faber, K.N.(1);Wijmenga, C.(2);Dijkstra, G.(1);Segal, E.(4,5);Fu, J.(2,3);Zhernakova, A.(2);Weersma, R.K.(1);
(1)University of Groningen- University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)University of Groningen- University Medical Center Groningen, Genetics, Groningen, The Netherlands;(3)University of Groningen- University Medical Center Groningen, Pediatrics, Groningen, The Netherlands;(4)Weizmann Institute of Science, Computer Science and Applied Mathematics, Rehovot, Israel;(5)Weizmann Institute of Science, Molecular Cell Biology, Rehovot, Israel;
DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tractECCO'22Year: 2022
Authors: Shilova, I.(1);La Chat, C.(1);Nigatu, E.(1);Messner, E.(1);Desnoyer, J.(1);Willcoxon, M.(1);Banas, S.(1);Ravichandar, D.(2);Narayan, N.(2);DeSantis, T.(2);Dabbagh, K.(1);Yamamoto, L.(1);
(1)Second Genome, Discovery, Brisbane, United States;(2)Second Genome, Bioinformatics, Brisbane, United States;
DOP55: Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative ColitisECCO'22Year: 2022
Authors: Leong, R.(1);Sands, B.(2);Peyrin-Biroulet, L.(3);Marano, C.(4);Miao, Y.(4);Izanec, J.(5);Feagan, B.(6);Rubin, D.(7); UNIFI Investigators
(1)Concord Repatriation General Hospital, Department of Gastroenterology, Concord, Australia;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Nancy University Hospital- Université de Lorraine, Inserm U954 and Department of Gastroenterology, Nancy, France;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Janssen Scientific Affairs- LLC, Immunology, Horsham, United States;(6)Western University and Alimentiv- Inc, Gastroenterology, London, Canada;(7)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;
